Cargando…

Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa

BACKGROUND: HIV endpoint-driven clinical trials increasingly provide oral pre-exposure prophylaxis (PrEP) as standard of prevention during the trial, however, among participants desiring to continue using PrEP at trial exit, little is known about post-trial PrEP access and continued use. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Beesham, Ivana, Milford, Cecilia, Smit, Jenni, Joseph Davey, Dvora L., Baeten, Jared M., Heffron, Renee, Beksinska, Mags, Mansoor, Leila E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286415/
https://www.ncbi.nlm.nih.gov/pubmed/37349816
http://dx.doi.org/10.1186/s12889-023-16139-z
_version_ 1785061743439904768
author Beesham, Ivana
Milford, Cecilia
Smit, Jenni
Joseph Davey, Dvora L.
Baeten, Jared M.
Heffron, Renee
Beksinska, Mags
Mansoor, Leila E.
author_facet Beesham, Ivana
Milford, Cecilia
Smit, Jenni
Joseph Davey, Dvora L.
Baeten, Jared M.
Heffron, Renee
Beksinska, Mags
Mansoor, Leila E.
author_sort Beesham, Ivana
collection PubMed
description BACKGROUND: HIV endpoint-driven clinical trials increasingly provide oral pre-exposure prophylaxis (PrEP) as standard of prevention during the trial, however, among participants desiring to continue using PrEP at trial exit, little is known about post-trial PrEP access and continued use. METHODS: We conducted one-time, semi-structured, face-to-face, in-depth interviews with 13 women from Durban, South Africa, from November to December 2021. We interviewed women who initiated oral PrEP as part of the HIV prevention package during the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial, elected to continue using PrEP at study exit, and were given a 3-month PrEP supply and referred to facilities for PrEP refills at the final trial visit. The interview guide probed for barriers and enablers to post-trial PrEP access, and current and future PrEP use. Interviews were audio-recorded and transcribed. Thematic analysis was facilitated using NVivo. RESULTS: Of the 13 women, six accessed oral PrEP post-trial exit, but five later discontinued. The remaining seven women did not access PrEP. Barriers to post-trial PrEP access and continued use included PrEP facilities having long queues, inconvenient operating hours, and being located far from women’s homes. Some women were unable to afford transport costs to collect PrEP. Two women reported visiting their local clinics and requesting PrEP but were informed that PrEP was unavailable at the clinic. Only one woman was still using PrEP at the time of the interview. She reported that the PrEP facility was located close to her home, staff were friendly, and PrEP education and counselling were provided. Most women not on PrEP reported wanting to use it again, particularly if barriers to access could be alleviated and PrEP was easily available at facilities. CONCLUSIONS: We identified several barriers to post-trial PrEP access. Strategies to enhance PrEP access such as a reduction in waiting queues, convenient facility operating hours, and making PrEP more widely available and accessible are needed. It is also worth noting that oral PrEP access has expanded in South Africa from 2018 till now and this could improve access to PrEP for participants exiting trials who desire to continue PrEP.
format Online
Article
Text
id pubmed-10286415
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102864152023-06-23 Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa Beesham, Ivana Milford, Cecilia Smit, Jenni Joseph Davey, Dvora L. Baeten, Jared M. Heffron, Renee Beksinska, Mags Mansoor, Leila E. BMC Public Health Research BACKGROUND: HIV endpoint-driven clinical trials increasingly provide oral pre-exposure prophylaxis (PrEP) as standard of prevention during the trial, however, among participants desiring to continue using PrEP at trial exit, little is known about post-trial PrEP access and continued use. METHODS: We conducted one-time, semi-structured, face-to-face, in-depth interviews with 13 women from Durban, South Africa, from November to December 2021. We interviewed women who initiated oral PrEP as part of the HIV prevention package during the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial, elected to continue using PrEP at study exit, and were given a 3-month PrEP supply and referred to facilities for PrEP refills at the final trial visit. The interview guide probed for barriers and enablers to post-trial PrEP access, and current and future PrEP use. Interviews were audio-recorded and transcribed. Thematic analysis was facilitated using NVivo. RESULTS: Of the 13 women, six accessed oral PrEP post-trial exit, but five later discontinued. The remaining seven women did not access PrEP. Barriers to post-trial PrEP access and continued use included PrEP facilities having long queues, inconvenient operating hours, and being located far from women’s homes. Some women were unable to afford transport costs to collect PrEP. Two women reported visiting their local clinics and requesting PrEP but were informed that PrEP was unavailable at the clinic. Only one woman was still using PrEP at the time of the interview. She reported that the PrEP facility was located close to her home, staff were friendly, and PrEP education and counselling were provided. Most women not on PrEP reported wanting to use it again, particularly if barriers to access could be alleviated and PrEP was easily available at facilities. CONCLUSIONS: We identified several barriers to post-trial PrEP access. Strategies to enhance PrEP access such as a reduction in waiting queues, convenient facility operating hours, and making PrEP more widely available and accessible are needed. It is also worth noting that oral PrEP access has expanded in South Africa from 2018 till now and this could improve access to PrEP for participants exiting trials who desire to continue PrEP. BioMed Central 2023-06-22 /pmc/articles/PMC10286415/ /pubmed/37349816 http://dx.doi.org/10.1186/s12889-023-16139-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Beesham, Ivana
Milford, Cecilia
Smit, Jenni
Joseph Davey, Dvora L.
Baeten, Jared M.
Heffron, Renee
Beksinska, Mags
Mansoor, Leila E.
Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa
title Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa
title_full Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa
title_fullStr Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa
title_full_unstemmed Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa
title_short Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa
title_sort post-trial access to and use of pre-exposure prophylaxis in durban, south africa
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286415/
https://www.ncbi.nlm.nih.gov/pubmed/37349816
http://dx.doi.org/10.1186/s12889-023-16139-z
work_keys_str_mv AT beeshamivana posttrialaccesstoanduseofpreexposureprophylaxisindurbansouthafrica
AT milfordcecilia posttrialaccesstoanduseofpreexposureprophylaxisindurbansouthafrica
AT smitjenni posttrialaccesstoanduseofpreexposureprophylaxisindurbansouthafrica
AT josephdaveydvoral posttrialaccesstoanduseofpreexposureprophylaxisindurbansouthafrica
AT baetenjaredm posttrialaccesstoanduseofpreexposureprophylaxisindurbansouthafrica
AT heffronrenee posttrialaccesstoanduseofpreexposureprophylaxisindurbansouthafrica
AT beksinskamags posttrialaccesstoanduseofpreexposureprophylaxisindurbansouthafrica
AT mansoorleilae posttrialaccesstoanduseofpreexposureprophylaxisindurbansouthafrica